Ask AI
CDH6 Ovarian Cancer

CME

Next-Generation CDH6-Targeting Antibody–Drug Conjugates in Ovarian Cancer: The Science, Strategy, and Signals to Inform Clinical Readiness

Physicians: Maximum of 0.75 AMA PRA Category 1 Credit

Released: January 26, 2026

Expiration: July 25, 2026

Activity

Progress
1 2
Course Completed

References

  1. Casal JI, Bartolomé RA. Beyond N-Cadherin, Relevance of cadherins 5, 6 and 17 in cancer progression and metastasis. Int J Mol Sci. 2019;20:3373.
  2. Shintani D, Hanaoka M, Sato S, et al. Clinical significance of cadherin-6 expression in primary and recurrent epithelial ovarian cancer and its association with outcomes: a potential therapeutic target for epithelial ovarian cancer. Presented at: Society of Gynecologic Oncology 2022 Annual Meeting on Women's Cancer; March 18-21, 2022. Abstract 206
  3. Ma C, Zhao JZ, Lin RT, et al. Combined overexpression of cadherin 6, cadherin 11 and cluster of differentiation 44 is associated with lymph node metastasis and poor prognosis in oral squamous cell carcinoma. Oncol Lett. 2018;15:9498-506.
  4. Bartolomé RA, Robles J, Martin‐Regalado Á, et al. CDH6‐activated αIIbβ3 crosstalks with α2β1 to trigger cellular adhesion and invasion in metastatic ovarian and renal cancers. Mol Oncol. 2021;15:1849-1865.
  5. Shimazui T, Yoshikawa K, Uemura H, et al. The level of cadherin-6 mRNA in peripheral blood is associated with the site of metastasis and with the subsequent occurrence of metastases in renal cell carcinoma. Cancer. 2004;101:963-968.
  6. Paul R, Ewing CM, Robinson JC, et al. Cadherin-6, a cell adhesion molecule specifically expressed in the proximal renal tubule and renal cell carcinoma. Cancer Res. 1997;57:2741-2748.
  7. Shintani D, Hanaoka M, Kaneda Y, et al. Targeting cadherin-6 in epithelial ovarian cancer: Clinical significance of its expression and efficacy of raludotatug deruxtecan (R-DXd) in patient-derived cell models. Presented at: European Society for Medical Oncology Congress; October 20-24, 2023. Abstract 777P.
  8. Ray-Coquard IL, Hasegawa K, Colombo N, et al. Raludotatug deruxtecan (R-DXd) in patients (pts) with platinum-resistant ovarian cancer (PROC): Primary analysis of the phase II dose-optimization part of REJOICE-Ovarian01. Presented at: European Society for Medical Oncology Congress; October 17-21, 2025. Abstract LBA 42.
  9. Bialucha CU, Collins SD, Li X, et al. Discovery and optimization of HKT288, a cadherin-6–targeting ADC for the treatment of ovarian and renal cancers. Cancer Discov. 2017;7:1030-1045.
  10. Suzuki H, Nagase S, Saito C, et al. Raludotatug deruxtecan, a CDH6-targeting antibody–drug conjugate with a DNA topoisomerase I inhibitor DXd, is efficacious in human ovarian and kidney cancer models. Mol Cancer Ther. 2024;23:257-271.
  11. Schöffski P, Concin N, Suarez C, et al. A phase 1 study of a CDH6-targeting antibody-drug conjugate in patients with advanced solid tumors with evaluation of inflammatory and neurological adverse events. Oncol Res Treat. 2021;44:547-556.
  12. Nakada T, Sugihara K, Jikoh T, et al. The latest research and development into the antibody–drug conjugate, [fam-] trastuzumab deruxtecan (DS-8201a), for HER2 cancer therapy. Chem Pharm Bull. 2019;67:173-185.
  13. Moore KN, Philipovskiy A, Harano K, et al. 745MO Raludotatug deruxtecan (R-DXd; DS-6000) monotherapy in patients with previously treated ovarian cancer (OVC): Subgroup analysis of a first-in-human phase I study. Presented at: European Society for Medical Oncology Congress; October 20-24, 2023. Abstract 745MO.
  14. Moore K, Philipovskiy A, Harano K, et al. Raludotatug deruxtecan monotherapy among patients with previously treated ovarian cancer: Subgroup analysis of a first-in-human phase I study. Presented at: Society of Gynecologic Oncology 2024 Annual Meeting on Women's Cancer; March 16-18, 2024. Abstract 04 [LBA].
  15. Moore KN, Philipovskiy A, Sudo K, et al. 77MO Raludotatug deruxtecan (R-DXd) monotherapy in patients (pts) with heavily pretreated platinum-sensitive ovarian cancer (PSOC): Subgroup analysis of a phase I study. Presented at European Society for Medical Oncology Gynaecological Cancers Congress 2025. Abstract 77MO.
  16.  Bouberhan S, Pujade-Lauraine E, Cannistra SA. Advances in the Management of Platinum-Sensitive Relapsed Ovarian Cancer. J Clin Oncol. 2019;37:2424.
  17. Harter P, Marth C, Mouret-Reynier MA, et al. Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial. Annals of Oncology. 2025;36:185.
  18. Albiges L, Harano K, Moore KN, et al. REJOICE-PanTumor01: A phase 2 signal-seeking study of raludotatug deruxtecan (R-DXd) in patients with advanced or metastatic gynecologic or genitourinary tumors. Presented at: 2025 Annual Meeting of the American Society of Clinical Oncology; May 30-June 3, 2025. Abstract 472b
  19. Oaknin A, Call JA, Shapira-Frommer R, et al. 126TiP REJOICE-Ovarian02: A phase Ib/II study of raludotatug deruxtecan (R-DXd) with other anticancer agents in participants (pts) with relapsed ovarian cancer (OC) after platinum-based chemotherapy. European Society for Medical Oncology Gynaecological Cancers Congress 2025. Abstract 126TiP.
  20. Shapira-Frommer R, Call J, Richardson D, et al. REJOICE-OVARIAN02: a phase 1b/2 study of raludotatug deruxtecan with other anticancer agents in participants with relapsed ovarian cancer after platinum-based chemotherapy. Presented at International Society of Gynecologic Cancer Global Meeting 2025. Abstract TP016.
  21. Lu W, Shi J, Liu SH, et al. CUSP06/AMT-707, a new CDH6-targeting antibody-drug conjugate, demonstrates potent antitumor activity in preclinical models. Presented at: American Association for Cancer Research Annual Meeting; April 14-19, 2023. Abstract 6320.
  22. Lu W, Shi J, Zhang W, Covino N, Penticoff A, Phillips R, et al. CUSP06, a novel CDH6-targeted antibody-drug conjugate, demonstrates antitumor efficacy in multiple CDH6-expressing human cancer models. Pharmaceutics. 2025;17:1049.
  23. Patel MR, Falchook GS, Lee EK, et al. First-in-human (FIH) phase 1 study of CUSP06, a cadherin-6 (CDH6)-directed antibody-drug conjugate (ADC), in patients with platinum-refractory/resistant ovarian cancer and other advanced solid tumors. Presented at: Annual Meeting of the American Society of Clinical Oncology; May 30-June 3, 2025. Abstract 3042
  24. Simcere Innovation. SIM0505, an ADC candidates Simcere Zaiming developed using proprietary technology platform, is entering trials both in China and the USA. simcere.com/en/news/detail.aspx?mtt=1483. Accessed January 14, 2025.
  25. Scalici J, Finan MA, Black J, et al. Minority participation in Gynecologic Oncology Group (GOG) Studies. Gynecol Oncol. 2015;138:441-444.
  26. Smith AJB, Alvarez R, Heintz J, et al. Disparities in clinical trial participation in ovarian cancer: A real-world analysis. Gynecol Oncol. 2023;175:25-31.
  27. Richardson MT, Barry D, Steinberg JR, et al. Underrepresentation of racial and ethnic minority groups in gynecologic oncology: An analysis of over 250 trials. Gynecologic Oncology. 2024;181:1-7.
  28. Johnson CR, Francoeur AA, Grewal A, et al. Trial enrollment and survival disparities among patients with advanced epithelial ovarian carcinoma. JAMA Netw Open. 2025;8:e2538648.
  29. Durant RW, Wenzel JA, Scarinci IC, et al. Perspectives on barriers and facilitators to minority recruitment for clinical trials among cancer center leaders, investigators, research staff, and referring clinicians: Enhancing minority participation in clinical trials (EMPaCT). Cancer. 2014;120:1097-1105.
  30. Patel KB, Pyrzak A, Williams H, et al. Participation in clinical trials may overcome health disparities in the treatment of advanced or recurrent epithelial ovarian cancer. Presented at: Society of Gynecologic Oncology 2018 Annual Meeting on Women's Cancer; March 24-27, 2018. Abstract 6.
  31. American Association for Cancer Research. AACR pediatric cancer progress report 2025. cancerprogressreport.aacr.org/wp-content/uploads/sites/2/2025/12/AACR_PCPR_2025.pdf. Accessed January 14, 2026.
  32. Lupo PJ, Siegel DA, Schussler NC, et al. Enrollment in Children’s Oncology Group’s clinical trials: population-based linkage with the National Childhood Cancer Registry. J Natl Cancer Inst. 2025;117:1868-1874.
  33. Unger JM, Shulman LN, Facktor MA, et al. National estimates of the participation of patients with cancer in clinical research studies based on Commission on Cancer accreditation data. J Clin Oncol. 2024;42:2139-2148.